Evolving calciphylaxis—what randomized, controlled trials can contribute to the capture of rare diseases

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 5, 2015, Pages 726-728

  Ketteler, Markus ^a   Biggar, Patrick H ^a  

^a KLINIKUM COBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; OSTEOCALCIN; PARATHYROID HORMONE; WARFARIN; CALCIMIMETIC AGENT;

ATRIAL FIBRILLATION; BONE TURNOVER; CALCINOSIS; DIABETES MELLITUS; DIALYSIS; DYSLIPIDEMIA; EDITORIAL; HUMAN; HYPERPHOSPHATEMIA; INFLAMMATION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SUPERINFECTION; VITAMIN K DEFICIENCY; CALCIPHYLAXIS; FEMALE; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE;

CALCIMIMETIC AGENTS; CALCIPHYLAXIS; CINACALCET HYDROCHLORIDE; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE;

EID: 84929177740     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03350315     Document Type: Editorial

References (10)

1. Brandenburg VM, Sinha S, Specht P, Ketteler M: Calcific uraemic arteriolopathy: A rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr Nephrol 29: 2289–2298, 2014
2. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS: The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol 10: 800–807, 2015
3. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367: 2482–2494, 2012
4. Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J: Vitamin K deficiency in CKD patients: A modifiable risk factor for vascular calcification? Kidney Int 76: 18–22, 2009
5. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y; Japanese Calciphylaxis Study Group: A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: 1580–1584, 2012
6. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, Breithardt G: Dilemmas in the management of atrial fibrillation in chronic kidney disease. J AmSoc Nephrol 20: 705–711, 2009
7. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL: Vitamins K and Dstatus in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 5: 590–597, 2010
8. Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ: Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 22: 387–395, 2011
9. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s002lbl.pdf. Accessed
10. Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R: Statin use and calcific uremic arteriolopathy: A matched case-control study. Am J Nephrol 37: 325–332, 2013